Funxional Therapeutics Limited

Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action

Older News

CAMBRIDGE, England - Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy